Diss. (sammanfattning) Stockholm : Karol. inst. / Härtill 5 uppsatser.

Xu Feng. / Thesis (Ph.D.)--Chinese University of Hong Kong, 1999. / Includes bibliographical references (p. 205-233). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

Diss. (sammanfattning) Stockholm : Karol. inst., 2002. / Härtill 6 uppsatser.

Thesis (doctoral)--Lund University, 1997. / Added t.p. with thesis statement inserted.

Thesis (doctoral)--Lund University, 1997. / Added t.p. with thesis statement inserted.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2005. / Härtill 5 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2005. / Härtill 5 uppsatser.

Thesis (Ph. D.)--Memorial University of Newfoundland, 1998. / Bibliography: leaves 93-101.

Abstract Deficiency of pulmonary surfactant is the main cause of respiratory distress syndrome (RDS) in premature newborn infants, which is often complicated by chronic lung disease (CLD). Preterm birth is often associated with intra-amniotic infection (IUI), which is characterized by increased proinflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α), in the amniotic fluid. In very preterm birth due to IUI, the incidence of RDS is decreased, while the incidence of CLD is increased. Maternal glucocorticoids are used in imminent preterm birth to prevent RDS. This study was designed to clarify the contrasting association of these perinatal pulmonary diseases with IUI and the pathogenesis of these lung diseases using an in vitro rabbit model. IL-1 increased the expression of surfactant protein (SP)-A and SP-B in very immature lung. Contrariwise, in transitional and mature fetal lung as well as in newborn lung, IL-1 additively with TNF-α decreased the expression of SP-B and SP-C. Bacterial lipopolysaccharide (LPS) decreased SP-A, -B and -C mRNAs in mature fetal and newborn lung, but had no effect on SP expression in immature lung. Interferon-γ (IFN-γ) had no effect on SP expression at any gestational age, but it modified the effects of the other cytokines. Dexamethasone (Dx) and IL-1 in combination additively increased SP-A and SP-B mRNAs in immature lung. Dx abolished the inhibitory effect of IL-1 on SP-B and SP-C in mature lung. Dx and IL-1 together tended to stabilize SP mRNAs. The present findings provide additional evidence of the role of the transcription factors nuclear factor-κB (NF-κB) and C/CAAT enhancer-binding protein δ (C/EBPδ) in the upregulation of SP-A by IL-1 in immature lung. Proinflammatory cytokines profoundly influence the expression of surfactant proteins in a manner that is strictly dependent on the length of gestation. The present findings help to explain the differences in the incidence of RDS and CLD in preterm births caused by IUI, and they may clarify further the role of surfactant in the pathogenesesis of lung diseases in neonatal infants. / Tiivistelmä Keuhkosurfaktantin puute aiheuttaa ennenaikaisesti syntyville keskosille vastasyntyneen hengitysvaikeusoireyhtymää eli RDS-tautia (Respiratory Distress Syndrome). Toinen keskosilla esiintyvä keuhkosairaus on krooninen keuhkosairaus eli CLD (Chronic Lung Disease). Glukokortikoideja käytetään hoitona ennenaikaisen synnytyksen uhatessa, koska niiden tiedetään vähentävän RDS-taudin riskiä. Kohdunsisäinen infektio on huomattava ennenaikaisen synnytyksen aiheuttaja. Infektiossa tulehduksen välittäjäaineet, kuten sytokiinit interleukiini-1 (IL-1) ja tuumorinekroositekijä alfa (TNF-α) lisääntyvät lapsivedessä. Infektiosta aiheutunut ennenaikainen synnytys vähentää RDS-taudin ilmaantumista pienille keskosille ja toisaalta lisää kroonisen keuhkosairauden riskiä. Tutkimuksen oli tavoitteena selvittää, miksi RDS ja CLD ilmaantuvat eriävästi infektion vuoksi ennenaikaisesti syntyneille vauvoille. Viljelemällä eri-ikäisten kanin sikiöiden sekä vastasyntyneiden kanin poikasten keuhkon kappaleita tutkittiin tulehduksen välittäjäaineiden sekä anti-inflammatorisen glukokortikoidin (deksametasonin) vaikutusta surfaktantin toiminnalle tarpeellisten surfaktanttiproteiinien (SP) ilmentymiseen. IL-1 lisäsi SP-A:n ja SP-B:n ilmentymistä erittäin epäkypsässä kanin sikiön keuhkossa. Toisaalta IL-1 ja TNF-α vähensivät SP-B:n ja SP-C:n ilmentymistä kypsemmässä sikiön sekä vastasyntyneen kanin keuhkossa. Interferoni-gamma (IFN-γ) ei vaikuttanut surfaktanttiproteiinien ilmentymiseen missään gestaatioiässä, mutta se muunsi muiden sytokiinien surfaktanttivaikutusta. Gram-negatiivisten bakteerien soluseinän tuote, lipopolysakkaridi (LPS) vähensi SP-A:n, SP-B:n ja SP-C:n ilmentymistä kypsässä kanin sikiön ja vastasyntyneen kanin keuhkossa. IL-1:llä ja deksametasonilla oli positiivinen yhteisvaikutus surfaktanttiproteiinien ilmentymiseen. Tämän surfaktanttiproteiineja lisäävän vaikutuksen mekanismiksi havaittiin pääasiallisesti lisääntynyt mRNA:n stabiliteetti. Lisäksi tutkimus antaa lisätietoa kahden transkriptiofaktorin, NF-κB:n (nuclear factor kappa B) ja C/EBPγ:n (C/CAAT enhancer binding protein delta), osuudesta IL-1:n aiheuttamassa SP-A:n ilmentymisen lisääntymisessä. Sytokiinien vaikutukset surfaktanttiproteiinien ilmentymiseen ovat riippuvaisia gestaatioiästä. Tutkimuksen löydökset auttavat ymmärtämään RDS:n ja CLD:n vastakohtaista esiintymismäärää keskosilla, joiden ennenaikainen synnytys on aiheutunut kohdunsisäisestä tulehduksesta. Edelleen tutkimus selittää glukokortikoidien positiivista vaikutusta hengitysvajaukseen johtavassa keuhkotulehduksessa.

INTRODUÇÃO: A Síndrome do Desconforto Respiratório (SDR) é uma das principais causas de morbi-mortalidade no período neonatal, acometendo predominantemente os recém-nascidos prematuros, devido a uma está deficiência de surfactante pulmonar. O Instituto Butantan desenvolveu um surfactante de origem porcina com objetivo de torná-lo disponível a todo Sistema Único de Saúde. O objetivo deste estudo foi avaliar, em um modelo experimental de SDR (coelho), a estabilidade do Surfactante Butantan (SB) um ano após sua produção e armazenamento a 2 a 8ºC.. MÉTODOS: 94 coelhos prematuros foram randomizados em dois grupos de tratamento: grupo Butantan e grupo Curosurf (controle), e foram analisados em seis momentos de avaliação: momento zero (imediatamente após a retirada do refrigerador ao final de 1 ano de armazenamento), momento 1 (24 horas após ter sido mantido a 24ºC), momento 2 (após 30 dias de armazenamento a 20º C), momento 3 (após 60 dias de armazenamento a 20º C), momento 4 (após 90 dias de armazenamento a 20º C) e momento 5 (após 180 dias de armazenamento a 20º C). Após receberem o surfactante, os animais foram ventilados por 15 minutos para avaliação da pressão ventilatória e complacência pulmonar dinâmica e curva pressão-volume pulmonar, seguindo-se à avaliação histopatológica dos pulmões. RESULTADOS: A eficácia do SB foi semelhante à do Curosurf, um ano após a sua produção e armazenamento a 2 a 8ºC. Neste momento de avaliação, não houve diferença estatisticamente significante entre os grupos de estudo quanto a: pressão ventilatória, complacência pulmonar dinâmica e curva pressão-volume pulmonar. Ao longo dos seis meses de armazenamento inadequado do SB, demonstrou-se a redução de sua eficácia durante a fase expiratória da curva pressão-volume pulmonar. No entanto, a análise histopatológica, demonstrou não haver diferença significante entre os dois grupos de estudo em nenhum dos momentos de avaliação. CONCLUSÕES: As propriedades bioquímicas do SB foram preservadas após um ano de sua produção e armazenamento em refrigeração de 2 a 8ºC. Condições inadequadas de armazenamento resultam em alterações das propriedades bioquímicas do SB e, conseqüentemente, de sua função, o que foi demonstrado por parâmetros de mecânica ventilatória, mas não pela análise histopatológica dos pulmões / INTRODUCTION: Respiratory Distress Syndrome (RDS) is one of the major causes of death among premature newborns, and its development results from surfactant deficiency. The Butantan Institute has recently produced a porcine-derived surfactant preparation in order to make it available nationwide for RDS treatment in the near future. The aim of this study was to evaluate, in an animal model of surfactant deficiency (premature rabbits), the stability of the Butantan Surfactant (SB) one year after its production and storage in the refrigerator, at 2 to 8ºC. METHODS: 94 premature newborn rabbits were randomized into two treatment groups: SB or Curosurf®(control surfactant), and were assessed in six different time-points: time-point zero (immediately after removal of surfactant from the refrigerator after one year of storage); time-point 1 (after 24h of storage at 24ºC), time-point 2 (after 30 days of storage at 20ºC), time-point 3 (after 60 days of storage at 20ºC), time-point 4 (after 90 days of storage at 20ºC) and time-point 5 (after 180 days of storage at 20ºC). The animals were artificially ventilated for 15 minutes for lung mechanics assessment (ventilatory pressure, dynamic lung compliance and pressure-lung volume curve), followed by removal of the lungs for histopathologic analysis. RESULTS: After one year of its production and storage at 2 to 8ºC, SB was as efficient as Curosurf. At this time-point, The Butantan Surfactant showed no significant differences with Curosurf® regarding the ventilatory pressure, dynamic lung compliance and pressure-lung volume curve. Throughout the six month period of warming, SB showed a decreasing efficiency, as revealed by the expiratory phase of the pressure-lung volume curve. However, the histopathologic analysis revealed no significant differences between the two groups, in any of the study time-points. CONCLUSIONS: The Butantan Surfactant preserved its biochemical properties one year after its production and storage at 2 to 8ºC. On the other hand, adverse storing conditions can lead to alterations in the SB biochemical properties that result in deterioration of its function, which was demonstrated in this study by changes in lung mechanics, but not in the histopathologic analysis